Breast cancer remains an ever-evolving challenge in the oncology sphere. The dynamic nature of the disease and its multiple subtypes mean that new investigational therapies are consistently being developed. The hope for these therapies lies in the focused clinical trials that test their safety and efficacy.
In this piece, we cast a lens on the present-day landscape of breast cancer trials, offering researchers a data-driven view into the clinical trial sphere, underpinned by Citeline’s real-world analytics. We also home in on Precision for Medicine’s long-standing and current expertise in breast cancer research.
Breast Cancer Clinical Trial Overview Using Citeline Insights
Breast cancer is one of the most common cancers among women worldwide. With early detection and treatment, survival rates have improved, but the disease still presents significant challenges. As per the latest statistics, there are more than 2 million new cases of breast cancer diagnosed annually. In the US alone, the year 2021 saw an estimated 281,550 new cases of invasive breast cancer among women. In the European Union, the numbers vary across countries, but cumulatively, the region witnesses approximately 404,920 new cases each year. It’s imperative to note that while breast cancer is predominantly a disease of women, men can also be affected, albeit in much smaller numbers.
Breast Cancer Research by Trial Status
According to Citeline as of January 31, 2024, there are 12,588 trials that have enrolled or plan to enroll breast cancer patients. This section presents a breakdown of breast cancer research trials based on their status. These data show a deep investment in breast cancer clinical research that continues today.
Breast Cancer Trials by Trial Status
Annual Breakdown of Planned & Ongoing Breast Cancer Trials
Here, we provide a year-by-year analysis of planned and ongoing breast cancer trials. This annual breakdown offers insights into the increase in pace and scale of research over time.
Planned & Ongoing Breast Cancer Trials by Start Date
Breast Cancer Trials: A Country-by-Country Analysis
This analysis offers a geographical perspective on breast cancer trials. These data highlight the global need for novel breast cancer therapeutics and the geographic reach required to execute some breast cancer clinical trials such as large registrational trials.
Planned & Ongoing Breast Cancer Trials by Site Country
Overview of Breast Cancer Trials by Subtype
This section provides a detailed look at breast cancer studies, segmented by breast cancer subtype. It offers a high-level understanding of the research efforts in the field across the main subtypes.
Breast Cancer Trials by Cancer Subtype
Breast Cancer Trials Across Phases
Here, we examine the distribution of breast cancer trials across different phases. This analysis provides insights into the maturity and potential of ongoing research.
Planned & Ongoing Breast Cancer Trials by Phase
Citeline, Trial Trove, Accessed 8 February 2024
Precision’s Expertise in Breast Cancer Research
At Precision for Medicine, our legacy in breast cancer research is not just a testament to our expertise but a reflection of our commitment to innovation and excellence. Our approach is characterized by a deep understanding of the disease’s complexities and a relentless pursuit of groundbreaking therapies.
Breast Cancer Clinical Trials Start with Precision
Precision is at the forefront of initiating and conducting breast cancer clinical trials. This section underscores our pivotal role in driving research forward.
Precision for Medicine’s Breast Cancer Trials by Start Date
Precision’s Breast Cancer Trials Span the Globe
Precision’s breast cancer trials are not confined to one region; they span the globe. This section highlights our global reach and the international impact of our research.
Precision for Medicine’s Breast Cancer Trial Experience by Country
Breast Cancer Trials by Phase
This section provides a detailed breakdown of breast cancer trials by phase. It offers insights into the progression of research from early to late stages.
Precision for Medicine’s Breast Cancer Trials by Phase
Precision’s Expertise by Cancer Subtype
Precision’s expertise extends to the various patient segments in breast cancer research. This chart provides a high-level view of Precision’s experience by breast cancer subtype, specifically HER2-positive (HER2+), Hormone Receptor Positive (Estrogen Receptor+ and Progesterone Receptor+), and Triple-Negative Breast Cancer (TNBC). This overview underscores our familiarity across the diverse landscape of breast cancer.
Precision for Medicine’s Breast Cancer Trials by Patient Subtype
Choosing Precision for Your Next Breast Cancer Clinical Trial
Breast cancer research is fraught with challenges, complexities, and constant evolution. The choice of a Clinical Research Organization (CRO) is a pivotal decision, one that can significantly influence the trajectory of a trial. Our expertise in managing complex trials, our commitment to advanced-stage research, and our proven track record make us the optimal choice for leading breast cancer trials.
As we continue to push the boundaries of what’s possible, our goal remains unwavering: to contribute significantly to the advancement of breast cancer treatments, ultimately improving patient outcomes and transforming lives worldwide.
